PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32582961-9 2020 Genistein increased the collagen and acid glycosaminoglycan content, as well as decreased the levels of TNF-alpha and IL-1beta. Genistein 0-9 tumor necrosis factor Rattus norvegicus 104-113 8370693-6 1993 The addition of genistein to rIL-1- and rTNF-alpha-stimulated trophoblasts inhibited rIL-1-induced and rTNF-alpha induced hCG production but maintained rIL-1- and rTNF-alpha-induced IL-6 production. Genistein 16-25 tumor necrosis factor Rattus norvegicus 40-50 8370693-6 1993 The addition of genistein to rIL-1- and rTNF-alpha-stimulated trophoblasts inhibited rIL-1-induced and rTNF-alpha induced hCG production but maintained rIL-1- and rTNF-alpha-induced IL-6 production. Genistein 16-25 tumor necrosis factor Rattus norvegicus 103-113 8370693-6 1993 The addition of genistein to rIL-1- and rTNF-alpha-stimulated trophoblasts inhibited rIL-1-induced and rTNF-alpha induced hCG production but maintained rIL-1- and rTNF-alpha-induced IL-6 production. Genistein 16-25 tumor necrosis factor Rattus norvegicus 103-113 34478828-6 2021 Meanwhile, G15 or JB1 could attenuate the anti-inflammatory effects of genistein in LPS-induced microglial activation and production of tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Genistein 71-80 tumor necrosis factor Rattus norvegicus 136-163 34478828-6 2021 Meanwhile, G15 or JB1 could attenuate the anti-inflammatory effects of genistein in LPS-induced microglial activation and production of tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Genistein 71-80 tumor necrosis factor Rattus norvegicus 165-174 34488288-8 2021 In addition, the genistein group had significantly lower levels of serum malondialdehyde (p=0.039) and tumor necrosis factor-alpha (p=0.003), and higher superoxide dismutase enzyme activity (p<0.001). Genistein 17-26 tumor necrosis factor Rattus norvegicus 103-130 34432988-8 2021 MCF and Genistein significantly reduced IL-1beta and TNFalpha levels that was elevated in serum of diabetic rats. Genistein 8-17 tumor necrosis factor Rattus norvegicus 53-61 34432988-10 2021 In conclusion, MCF and Genistein ameliorate type 2 diabetes complications by preventing the loss of insulin-positive cells, inhibiting IL-1beta and TNFalpha and up-regulating proglucagon and insulin receptor mRNA expression. Genistein 23-32 tumor necrosis factor Rattus norvegicus 148-156 34432988-11 2021 Novelty: MCF and Genistein has an inhibitory effect on diabetic induced IL-1beta and TNFalpha production. Genistein 19-28 tumor necrosis factor Rattus norvegicus 87-95 33447176-8 2020 Genistein also effectively lowered fasting blood glucose, tartrate-resistant acid phosphatase 5b, tumor necrosis factor-alpha, interleukin-6, and numbers of adipocytes and osteoclasts. Genistein 0-9 tumor necrosis factor Rattus norvegicus 98-125 32083119-10 2019 Genistein treatment had positive effects on the condylar cartilage renovation, while high dose genistein treatment had more significant effects on the reversing of OA changes and reduction of the expression of p65 and inflammatory cytokines (IL-1beta and TNFalpha). Genistein 95-104 tumor necrosis factor Rattus norvegicus 255-263 30360615-9 2018 The proinflammatory cytokines TNF-alpha and IL-6 were alleviated by quercetin, genistein, and naringenin. Genistein 79-88 tumor necrosis factor Rattus norvegicus 30-39 30784939-9 2019 Moreover, genistein alone and/or in combination with metformin also downregulated the inflammatory responses by decreasing the levels of interleuin-6, tumor necrosis factor-alpha and C-reactive protein in serum (P < 0.05) and intestine (P < 0.001) more efficiently as compared to that of metformin-treated experimental animals. Genistein 10-19 tumor necrosis factor Rattus norvegicus 137-178 29102164-11 2018 In conclusion, genistein alleviated LPS-induced cognitive dysfunctions and neural inflammation attenuation of oxidative stress and AChE activity and appropriate modulation of Nrf2/NF-kappaB/IL-6/TNFalpha/COX2/iNOS/TLR4/GFAP. Genistein 15-24 tumor necrosis factor Rattus norvegicus 195-203 30287760-6 2018 Genistein induced an increase in the activity of SOD and the level of IL-10, while causing a decrease in NO, MDA, and TNF-alpha in injured spinal cord tissue. Genistein 0-9 tumor necrosis factor Rattus norvegicus 118-127 25620059-8 2015 In addition Genistein significantly suppressed the production of d-GalN-induced proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1beta. Genistein 12-21 tumor necrosis factor Rattus norvegicus 117-144 26092427-6 2015 Administration of genistein to diabetic rats resulted in a decrease in blood glucose (p < 0.001), % HbA1c (p < 0.0001), C-reactive protein (p < 0.001), and expression of TNF- alpha (p < 0.001) and TGF-beta1 (p < 0.0001) proteins. Genistein 18-27 tumor necrosis factor Rattus norvegicus 179-189 25620059-8 2015 In addition Genistein significantly suppressed the production of d-GalN-induced proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1beta. Genistein 12-21 tumor necrosis factor Rattus norvegicus 146-155 23678422-10 2011 There was a reduction in TNF-alpha, IL-6, adiponectin and leptin serum concentrations after treatment with genistein and daidzein. Genistein 107-116 tumor necrosis factor Rattus norvegicus 25-34 25358106-5 2014 GEN also restored the liver levels of malondialdehyde and reduced glutathione, as well as tumor necrosis factor-alpha, interleukin-6, and their modulator nuclear factor kappa-light-chain-enhancer of activated B cells. Genistein 0-3 tumor necrosis factor Rattus norvegicus 90-117 22901685-6 2013 Genistein inhibited IKKbeta and nuclear factor-kB (NF-kB) activation with down-regulation of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production and expression. Genistein 0-9 tumor necrosis factor Rattus norvegicus 93-120 22901685-6 2013 Genistein inhibited IKKbeta and nuclear factor-kB (NF-kB) activation with down-regulation of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production and expression. Genistein 0-9 tumor necrosis factor Rattus norvegicus 122-131 23627839-10 2013 Kinetic studies revealed that TNF-alpha inhibited Na(+)-Gln cotransport by reducing the affinity of the cotransporters for Gln, and this effect was antagonized by genistein. Genistein 163-172 tumor necrosis factor Rattus norvegicus 30-39 20426659-8 2010 Genistein treatment also decreased the levels of the inflammatory cytokines TNF-alpha, IL-1beta and TGF-beta and led to a reduction in collagen content, a reduction in 8-OHdG levels, and complete protection against DNA damage measured in surviving rats at 28 weeks after irradiation. Genistein 0-9 tumor necrosis factor Rattus norvegicus 76-85 21042558-13 2010 Genistein represses the release of TNF-alpha and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase inhibitor. Genistein 0-9 tumor necrosis factor Rattus norvegicus 35-44 19615317-0 2009 [Effects of genistein on interleukin-1beta and tumor necrosis factor-alpha secreted by fibroblast-like synoviocytes isolated from type II collagen-induced arthritis rats]. Genistein 12-21 tumor necrosis factor Rattus norvegicus 47-74 20923528-11 2009 CONCLUSIONS: Genistein activates the antioxidant profile, decreases IL-6 and TNF-alpha concentrations, prevents oxidative damage, and ameliorates fatty liver in insulin-resistant rats. Genistein 13-22 tumor necrosis factor Rattus norvegicus 77-86 19615317-9 2009 After administration of different concentrations of Gen (100, 200, 400 micromol/L), the contents of IL-1beta and TNF-alpha in supernatants of FLSs were decreased dose-dependently. Genistein 52-55 tumor necrosis factor Rattus norvegicus 113-122 19615317-10 2009 CONCLUSION: Genistein can suppress the secretion of TNF-alpha and IL-1beta in FLSs dose-dependently, which may be one of the mechanisms for genistein in inhibiting the arthromeningitis of CIA rats. Genistein 12-21 tumor necrosis factor Rattus norvegicus 52-61 19615317-10 2009 CONCLUSION: Genistein can suppress the secretion of TNF-alpha and IL-1beta in FLSs dose-dependently, which may be one of the mechanisms for genistein in inhibiting the arthromeningitis of CIA rats. Genistein 140-149 tumor necrosis factor Rattus norvegicus 52-61 17991490-9 2007 Benzo(a)pyrene also induced TNF-alpha and IL-1beta production in PMNs, which was significantly reversed by genistein. Genistein 107-116 tumor necrosis factor Rattus norvegicus 28-37 17914984-12 2007 CONCLUSIONS: Genistein, a strong antioxidant agent, significantly decreased the plasma TNF-alpha level and remarkably prevented the emergence of NASH by improving the biochemical and histopathological abnormalities via attenuating oxidative stress. Genistein 13-22 tumor necrosis factor Rattus norvegicus 87-96 11821008-8 2002 Topical application of ODQ and genistein, significantly inhibited increases in permeability of the blood-brain barrier to FITC-dextran-10K during application of TNF-alpha. Genistein 31-40 tumor necrosis factor Rattus norvegicus 161-170 17087054-8 2006 Experiments demonstrated that genistein administration resulted in significant suppression of WIR stress-induced gastric mucosal injury and MPO activity, Further, genistein significantly elevated SOD activity and significantly suppressed the TBARS level, production of TNF-alpha and CINC-1, and secretion of gastrin, histamine, and somatostatin. Genistein 163-172 tumor necrosis factor Rattus norvegicus 269-278 15706233-4 2005 Genistein also inhibited lipopolysaccharide-induced microglia activation and production of tumor necrosis factor-alpha, nitric oxide and superoxide in mesencephalic neuron-glia cultures and microglia-enriched cultures. Genistein 0-9 tumor necrosis factor Rattus norvegicus 91-118 14680578-6 2003 After treated with genistein, BMD and the serum level of ALP, ACP, osteocalcin increased significantly, while the serum level of IL-1beta and TNF-alpha decreased. Genistein 19-28 tumor necrosis factor Rattus norvegicus 142-151 12817292-6 2003 Treatment of VSMCs with protein tyrosine kinase (PTK) inhibitor genistein or tyrphostin AG18 also reduced the NO production evoked by LPS, TNF-alpha or IL-1beta, which was associated with inhibition of iNOS protein expression. Genistein 64-73 tumor necrosis factor Rattus norvegicus 139-148 12808286-12 2003 In vivo, after treated with genistein, BMD and the serum level of ALP, ACP, osteocalcin increased significantly, while the serum level of IL-1beta and TNFalpha decreased. Genistein 28-37 tumor necrosis factor Rattus norvegicus 151-159 10657625-7 2000 OX8 (CD8 alpha)-induced TNF and IL-1 beta production by macrophages was blocked by inhibitors of protein tyrosine kinase(s), PP1, and genistein, but not by phosphatidylinositol-3 kinase inhibitor, wortmannin. Genistein 134-143 tumor necrosis factor Rattus norvegicus 24-27 10588923-12 1999 Administration of genistein (1 mg kg(-1), i.v., 5 min after coronary artery occlusion) lowered myocardial necrosis and MPO activity in the area-at-risk and in the necrotic area, decreased serum CPK activity, increased myocardial contractility, decreased the occurrence of ventricular arrhythmias, reduced serum and macrophages levels of TNF-alpha and blunted ICAM-1 expression in the injured myocardium. Genistein 18-27 tumor necrosis factor Rattus norvegicus 337-346 10588923-13 1999 Finally genistein added in vitro to peritoneal macrophages collected from untreated rats subjected to myocardial ischaemia-reperfusion injury significantly reduced TNF-alpha production. Genistein 8-17 tumor necrosis factor Rattus norvegicus 164-173 10482916-11 1999 Genistein (tyrosine kinase inhibitor, 2.5 mg kg-1, s.c.) or PD 098059 (MAP-kinase inhibitor, 30 nmol) produced marked inhibition of des-Arg9-BK-induced oedema (58 and 39% for IL-1beta and 31 and 35% for TNFalpha respectively). Genistein 0-9 tumor necrosis factor Rattus norvegicus 203-211 9048615-7 1997 Furthermore, using genistein to inhibit tyrosine kinase activity, we not only blocked the action of TGF alpha on PAI-1 [initiated upon binding to the tyrosine kinase epidermal growth factor/TGF alpha receptor (EGFR)], but also markedly reduced that of TNF alpha. Genistein 19-28 tumor necrosis factor Rattus norvegicus 252-261 10415163-9 1999 Inhibition of tyrosine phosphorylation by genistein prevented the reorganization of the actin cytoskeleton by TNF-alpha. Genistein 42-51 tumor necrosis factor Rattus norvegicus 110-119 9444616-4 1997 The increase in TNF alpha caused by stimulation of J774.2 macrophages was abolished by pretreatment of cells with (i) the protein synthesis inhibitor cycloheximide, (ii) with the selective ETA-receptor antagonists BQ-123 or BQ-485 (but not the selective ETB-receptor antagonist BQ-788), (iii) the tyrosine kinase inhibitors genistein or tyrphostin AG126, or (iv) with the glucocorticoid, dexamethasone. Genistein 324-333 tumor necrosis factor Rattus norvegicus 16-25 9298529-15 1997 Genistein, but not daidzein, also reduced the rise in the serum levels of TNF alpha caused by LPS. Genistein 0-9 tumor necrosis factor Rattus norvegicus 74-83 9124343-3 1997 Genistein inhibited tumor necrosis factor-alpha (TNF-alpha)-stimulated induction of NOS activity and NOS protein in a dose-dependent manner. Genistein 0-9 tumor necrosis factor Rattus norvegicus 20-47 9124343-3 1997 Genistein inhibited tumor necrosis factor-alpha (TNF-alpha)-stimulated induction of NOS activity and NOS protein in a dose-dependent manner. Genistein 0-9 tumor necrosis factor Rattus norvegicus 49-58 9124343-4 1997 Genistein also impaired TNF-alpha-induced NOS mRNA accumulation, suggesting protein tyrosine kinase regulation of NOS induction occurred at the level of transcription-translation. Genistein 0-9 tumor necrosis factor Rattus norvegicus 24-33